Recent Updates
Recently added Catalysts

SSGJ-706

Phase 2

First-line Advanced NSCLC Patients | Small molecule | Other |Sunshine Biopharma Inc.|Last Updated: Dec 18, 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

ACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment240

FDA Designations

No designations recorded

Clinical trial landscape

SSGJ-706 · 1 trial · 1 indication

Phase 2 1
NCT07171606A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） PatientsFirst-line Advanced NSCLC Patients
RECRUITING240 Analytics
PHASE2RECRUITING
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
First-line Advanced NSCLC Patients
NCT07171606240
Unlock trial analytics

Study Endpoints

Primary Endpoints

Objective response rate (ORR)
12 months
Incidence and severity of Adverse Events
12 months

Secondary Endpoints

DCR : Disease Control Rate
12 months
PFS：Progression-Free Survival
24 month
OS：Overall Survival
24 month
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
dose level 1 of SSGJ-706 monotherapyEXPERIMENTAL -
dose level 2 of SSGJ-706 monotherapyEXPERIMENTAL -
dose level 1 of SSGJ-706 combined with chemotherapyEXPERIMENTAL -
dose level 2 of SSGJ-706 combined with chemotherapyEXPERIMENTAL -
PD-1/L1 combined with chemotherapyACTIVE_COMPARATOR -

Interventions

NameTypeDescription
SSGJ-706DRUGPD-1/PD-L1 bispecific antibody
pemetrexed /carboplatinDRUGchemotherapy
Carboplatin/PaclitaxelDRUGchemotherapy
PD-1 Inhibitor + ChemotherapyDRUGcontrol group
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Males and/or females over age 18 2. Histologically and/or cytologically documented local advanced or metastatic NSCLC . 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 4. Expected survival \>=3 months. 5. Signed informed consent form. Exclusion Criter...

Countries:China
Unlock Eligibility Criteria

Frequently asked questions about SSGJ-706

What is SSGJ-706 used for?

SSGJ-706 is an investigational small molecule being studied for first-line advanced non-small cell lung cancer (NSCLC) and for gastric/gastroesophageal junction adenocarcinoma. It is also being evaluated in combination therapy for advanced gastrointestinal cancers, including metastatic colorectal cancer, pancreatic ductal adenocarcinoma, and oesophageal cancer.

Who makes SSGJ-706?

SSGJ-706 is being developed by Sunshine Biopharma Inc., a biopharmaceutical company listed on the stock exchange under the ticker SBFM. The company is conducting clinical trials for this investigational drug in China.

What phase is SSGJ-706 in?

SSGJ-706 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials are listed, one recruiting and one not yet recruiting, with a combined planned enrollment of 300 patients.

What clinical trials is SSGJ-706 in?

SSGJ-706 is being studied in two Phase 2 trials. NCT07171606 is a recruiting study of SSGJ-706 monotherapy and combination therapy in advanced NSCLC with 240 patients. NCT07233850 is a not-yet-recruiting study of SSGJ-706 in combination therapy for advanced gastrointestinal cancers with 300 patients.

Is SSGJ-706 the same as SSGJ-706+XELOX?

SSGJ-706+XELOX is an alternative name for SSGJ-706, referring to the drug when used in combination with the chemotherapy regimen XELOX. The drug itself is SSGJ-706, and the combination name is used in the context of its clinical development.